Laurus Labs Limited
LAURUSLABS.NS

$3.71 B
Marketcap
$6.87
Share price
Country
$0.19
Change (1 day)
$6.95
Year High
$4.23
Year Low

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.

marketcap

P/E ratio for Laurus Labs Limited (LAURUSLABS.NS)

P/E ratio as of 2023: 135.99

According to Laurus Labs Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 135.99. At the end of 2022 the company had a P/E ratio of 19.94.

P/E ratio history for Laurus Labs Limited from 2012 to 2023

PE ratio at the end of each year

Year P/E ratio
2023 135.99
2022 19.94
2021 38.28
2020 19.72
2019 13.57
2018 44.89
2017 32.13
2016 24.56
2015 29.16
2014 43.40
2013 30.23
2012 44.27